	US 12,404,555 B2
	Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
Vinay K. Jain, Dallas, TX (US)
Assigned to Arog Pharmaceuticals, Inc., Plano, TX (US)
Filed by Arog Pharmaceuticals, Inc., Plano, TX (US)
Filed on Jun. 23, 2021, as Appl. No. 17/355,468.
Application 17/355,468 is a continuation of application No. 15/799,684, filed on Oct. 31, 2017, granted, now 11,078,541.
Claims priority of provisional application 62/416,475, filed on Nov. 2, 2016.
Prior Publication US 2021/0324481 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 31/4709 (2013.01); A61K 45/06 (2013.01); G01N 33/57492 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/912 (2013.01)]

5 Claims

1. A method for treating human patient suffering from leukemia with crenolanib, where the leukemia is characterized by one or more deregulated FLT3 receptors, or one or more constitutively active FLT3 receptors, and one or more driver mutations in a DNMT3A gene, the method comprising:

first, obtaining a biological sample from a human patient's leukemia;

then assaying the biological sample for expression of the deregulated FLT3 receptor or the constitutively active FLT3 receptor, and expression of one or more driver mutations in the DNMT3A gene;

then determining that the human patient has a poor prognosis of leukemia based on the detection of the deregulated FLT3 receptor or the constitutively active FLT3 receptor, and the presence of the one or more driver mutations in the DNMT3A gene; and

then administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, thereby treating the leukemia which has both the deregulated FLT3 receptor or the constitutively active FLT3 receptor and the one or more driver mutations in the DNMT3A gene.